Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II mosunetuzumab study in diffuse large B-cell lymphoma
MOH_2018-08-30_003622Phase 2Recruiting
- Sponsor
- Roche
- Start
- Aug 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of mosunetuzumab and polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by Roche. Primary endpoints: Safety, Pharmacokinetics and 1 more. Started Aug 2018; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2018-08-30_003622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-30_003622.